Suppr超能文献

澳大利亚腹膜透析患者中的棒状杆菌性腹膜炎:82 例患者的预测因素、治疗和结局。

Corynebacterium peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases.

机构信息

Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia.

出版信息

Nephrol Dial Transplant. 2009 Dec;24(12):3834-9. doi: 10.1093/ndt/gfp322. Epub 2009 Jul 2.

Abstract

BACKGROUND

Infection due to Corynebacterium species has been reported with increasing frequency over recent decades. The impacts of enhanced laboratory detection together with widespread use of new peritoneal dialysis (PD) connection technology and antimicrobial prophylaxis strategies on Corynebacterium PD-associated peritonitis have not been well studied.

METHODS

We investigated the frequency, predictors, treatment and clinical outcomes of Corynebacterium peritonitis in all Australian adult patients involving 66 centres who were receiving PD between 1 October 2003 and 31 December 2006.

RESULTS

Eighty-two episodes of Corynebacterium peritonitis (2.3% of all peritonitis episodes) occurred in 65 (1.4%) PD patients. Ten (15%) patients experienced more than one episode of Corynebacterium peritonitis and additional organisms were isolated in 12 (15%) episodes of Corynebacterium peritonitis. The incidence of Corynebacterium peritonitis was significantly and independently predicted only by BMI: RR 2.72 (95% CI 1.38-5.36) for the highest tertile BMI compared with the lowest tertile. The overall cure rate with antibiotics alone was 67%, which was similar to that of peritonitis due to other organisms. Vancomycin was the most common antimicrobial agent administered in the initial empiric and subsequent antibiotic regimens, although outcomes were similar regardless of antimicrobial schedule. Corynebacterium peritonitis not infrequently resulted in relapse (18%), repeat peritonitis (15%), hospitalization (70%), catheter removal (21%), permanent haemodialysis transfer (15%) and death (2%). The individuals who had their catheters removed more than 1 week after the onset of Corynebacterium peritonitis had a significantly higher risk of permanent haemodialysis transfer than those who had their catheters removed within 1 week (90% versus 43%, P < 0.05).

CONCLUSIONS

Corynebacterium is an uncommon but significant cause of PD-associated peritonitis. Complete cure with antibiotics alone is possible in the majority of patients, and rates of adverse outcomes are comparable to those seen with peritonitis due to other organisms. Use of vancomycin rather than cephazolin as empiric therapy does not impact outcomes, and a 2-week course of antibiotic therapy appears sufficient. If catheter removal is required, outcomes are improved by removing the catheter within 1 week of peritonitis onset.

摘要

背景

近年来,由于棒状杆菌属引起的感染报告频率不断增加。实验室检测能力的提高以及新型腹膜透析(PD)连接技术和抗菌预防策略的广泛应用对与 PD 相关的棒状杆菌腹膜炎的影响尚未得到很好的研究。

方法

我们研究了 2003 年 10 月 1 日至 2006 年 12 月 31 日期间在澳大利亚 66 个中心接受 PD 治疗的所有成年患者中棒状杆菌腹膜炎的频率、预测因素、治疗和临床结局。

结果

65 例 PD 患者(占所有腹膜炎患者的 1.4%)发生 82 例棒状杆菌腹膜炎(腹膜炎的 2.3%)。10 例(15%)患者经历了一次以上的棒状杆菌腹膜炎,12 例(15%)棒状杆菌腹膜炎中分离出了其他病原体。BMI 是唯一能显著独立预测棒状杆菌腹膜炎发生率的因素:与最低三分位 BMI 相比,最高三分位 BMI 的 RR 为 2.72(95%CI 1.38-5.36)。单独使用抗生素的总治愈率为 67%,与其他病原体引起的腹膜炎相似。万古霉素是初始经验性和后续抗生素方案中最常用的抗菌药物,尽管无论使用何种抗菌药物方案,结果相似。棒状杆菌腹膜炎常导致复发(18%)、再次腹膜炎(15%)、住院(70%)、导管拔除(21%)、永久性血液透析转移(15%)和死亡(2%)。棒状杆菌腹膜炎发病后 1 周以上拔除导管的患者,与 1 周内拔除导管的患者相比,永久性血液透析转移的风险显著更高(90%比 43%,P < 0.05)。

结论

棒状杆菌是 PD 相关腹膜炎的一种不常见但重要的原因。大多数患者单独使用抗生素即可完全治愈,不良结局的发生率与其他病原体引起的腹膜炎相似。使用万古霉素而非头孢唑啉作为经验性治疗不会影响结局,2 周疗程的抗生素治疗似乎足够。如果需要拔除导管,在腹膜炎发病后 1 周内拔除导管可改善结局。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验